Tag: Zydus
Zydus receives WHO’s approval for ‘Usnoflast’ as recommended name for ZYIL1
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Zydus gets USFDA nod for Phase II clinical trial of ZYIL1...
The Phase 2 study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics in patients with Parkinson’s Disease
Zydus acquires UK based LiqMeds
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026 depending on achievement of certain agreed milestones towards acquisition of the LiqMeds Group of companies
Zydus Lifesciences initiates Phase II clinical trial of ZYIL1, a potential...
The USFDA has granted Zydus an ‘Orphan Drug Designation’ for ZYIL1 to treat patients with Cryopyrin Associated Periodic Syndrome (CAPS), a rare auto-inflammatory disease
Zydus appoints Punit Patel as President & CEO to lead its...
Punit will be responsible for the business operations of all Zydus entities in North America which include generics, injectables and specialty business, rare and orphan disease portfolio
Zydus to present on ZYIL1 at the International Congress of Parkinson’s...
ZYIL1 decreased α synuclein expression and improved motor function in non-clinical models
of Parkinson’s Disease
Zydus Lifesciences acquires 6.5% stake in Mylab via its subsidiary ZAHIL
The acquisition represents collective vision to transform healthcare by combining therapeutic expertise in human formulations and diagnostic capabilities of the two companies
Zydus granted orphan drug designation by USFDA for ZYIL1 in treatment...
Orphan drug designation by USFDA for ZYIL1, provides eligibility for certain development incentives, including tax credits for qualified clinical testing, prescription drug user fee exemptions and seven-year marketing exclusivity
Zydus achieves positive Phase 2 Proof-of-Concept of NLRP3 inhibitor, ZYIL1 in...
The company is now planning to conduct further pivotal clinical trials and is committed to develop ZYIL1 for patients living with CAPS and other chronic inflammatory diseases
Zydus launches Bemdac to treat uncontrolled LDL-Cholesterol in India
Bempedoic acid based new class of drug treats uncontrolled LDL Cholesterol, despite the use of a maximum tolerate